Aunt Minnie (2/17) reports, “Imaging specialists who visually interpreted flortaucipir-PET images were able to determine a person’s risk of progressing to Alzheimer’s and mild cognitive impairment within the next 18 months, according to a study published February 15 in JAMA Neurology.” Researchers from “several academic institutions and Avid Radiopharmaceuticals, which developed and markets flortaucipir, found that approximately 70% of study participants with characteristics of advanced Alzheimer’s disease on visual interpretation of baseline PET scans experienced ‘clinically meaningful deterioration’ 18 months later.” By comparison, “less than half of the subjects with nonadvanced Alzheimer’s traits had similar levels of cognitive deterioration.” (SOURCE: APAHeadlines)